Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial

Kura targets a registrational study in 2028, positioning the regimen as a potential option following immunotherapy-based treatment.

Safety looked manageable, broadly matching known profiles of the two drugs, with side effects handled mainly through dosing adjustments.

A randomized Phase 1b study is enrolling in the U.S. and EU, testing the combination versus cabozantinib alone to set a recommended Phase 3 dose.

Kura Oncology disclosed updated Phase 1a results already presented at KCRS 2026 for darlifarnib with cabozantinib in advanced clear cell renal cell carcinoma.

The combination produced durable tumor shrinkage in a pretreated, cabozantinib-naïve population, supporting continued development in later-line settings.